Comparing anti-factor Xa and activated partial thromboplastin levels for monitoring unfractionated heparin.

被引：0
|
作者：
Wahking, Rebekah A. [1 ]
Hargreaves, Rachel H. [2 ]
Lockwood, Sean M. [3 ]
Haskell, Sabrina K. [2 ]
Davis, Kelly [2 ]
机构：
[1] Univ Kentucky, Coll Pharm, Lexington, KY USA
[2] Lexington VA Med Ctr, Dept Pharm, Lexington, KY USA
[3] Lexington VA Med Ctr, Dept Med, Lexington, KY USA
来源：
PHARMACOTHERAPY | 2018年 / 38卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
8E
引用
收藏
页码：E54 / E54
页数：1
相关论文
共 50 条
  • [1] Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin
    Wahking, Rebekah A.
    Hargreaves, Rachel H.
    Lockwood, Sean M.
    Haskell, Sabrina K.
    Davis, Kelly W.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 801 - 805
  • [2] Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience
    Woods, Gary M.
    Stanek, Joseph
    Harrison, Sheilah
    Texter, Karen
    Kerlin, Bryce A.
    Dunn, Amy L.
    Kumar, Riten
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (07) : 576 - +
  • [3] Interlaboratory Precision in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time
    Cuker, Adam
    Ptashkin, Beverly
    Konkle, Barbara A.
    Pipe, Steven W.
    Whinna, Herbert C.
    Zheng, X. Long
    Cines, Douglas B.
    Pollak, Eleanor
    [J]. BLOOD, 2008, 112 (11) : 166 - 166
  • [4] Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time
    Cuker, A.
    Ptashkin, B.
    Konkle, B. A.
    Pipe, S. W.
    Whinna, H. C.
    Zheng, X. L.
    Cines, D. B.
    Pollak, E. S.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (01) : 80 - 86
  • [5] ANTI-FACTOR XA VERSUS ACTIVATED PARTIAL THROMBOPLASTIN TIME FOR HEPARIN INFUSION MONITORING
    Jung, Sul
    Choi, Austin
    Lepore, Mark
    [J]. CRITICAL CARE MEDICINE, 2020, 48
  • [6] Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study
    Samuel, S.
    Allison, T. A.
    Sharaf, S.
    Yau, G.
    Ranjbar, G.
    Mckaig, N.
    Nguyen, A.
    Escobar, M.
    Choi, H. A.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (05) : 499 - 502
  • [7] Lack of Inter-Laboratory Agreement in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa Activity and the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time
    Toulon, Pierre
    Smahi, Motalib
    De Pooter, Neila
    Zereg, Elamine
    [J]. BLOOD, 2017, 130
  • [8] Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics
    Trucco, M.
    Lehmann, C. U.
    Mollenkopf, N.
    Streiff, M. B.
    Takemoto, C. M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) : 788 - 794
  • [9] Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time: a rebuttal
    Kitchen, S.
    Preston, F. E.
    Jennings, I.
    Kitchen, D. P.
    Woods, T. A. L.
    Walker, I.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (12) : 2157 - 2158
  • [10] Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time
    Coons, James C.
    Iasella, Carlo J.
    Thornberg, Megan
    Fitzmaurice, Mary Grace
    Goehring, Kimberly
    Jablonski, Lindsay
    Leader, Dominic
    Meyer, Abby
    Seo, Hangil
    Benedict, Neal J.
    Smith, Roy E.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (09) : 1015 - 1019
12345